Which specific retail supplement SKUs named LipoFit or LipoFit Turbo have been recalled or subject to FDA import alerts?
Executive summary
The available FDA notice names LipoFit Turbo as a product consumers should avoid, based on laboratory analysis that found undisclosed prescription drugs and diuretics in the formulation [1], but the documents provided in this reporting do not list any specific retail SKUs nor cite any FDA import alerts tied to products called “LipoFit” or “LipoFit Turbo” [1] [2] [3].
1. What the FDA public notice explicitly states
The FDA’s consumer advisory for LipoFit Turbo warns the public not to purchase or use the product and reports that FDA laboratory analysis confirmed the presence of sibutramine, metformin, fluoxetine, and furosemide that were not declared on the label, making the product potentially harmful [1]; the notice frames this as part of a larger pattern in which “dietary supplement” products marketed for weight loss and other uses have been found to contain hidden drug ingredients [1].
2. What the sources do not provide — no SKU or import-alert identifiers
The supplied FDA pages and archival recall listings include general mechanisms for recalls and health-fraud alerts [4] [2] [3] but the specific items in this packet do not include retail SKU numbers, lot codes, National Drug Code-like identifiers, or any FDA import-alert notices that explicitly name individual LipoFit or LipoFit Turbo SKUs; therefore no authoritative SKU-level recall or import-alert assertion can be made from these sources alone [1] [4] [2].
3. Why that gap matters — how FDA public notices are sometimes published
FDA public notices and health‑fraud recall lists will name products and sometimes include lot or distributor detail, but not every advisory translates into a formal posted recall entry or an import alert with SKU/lot data visible in the summary materials cited here [4] [2] [3]; moreover, previous analyses of FDA enforcement show that warning letters and public notices do not always result in manufacturer recalls or complete marketplace removals, and many adulterated supplements can remain available for years after agency action [5].
4. Risk context from recent supplement enforcement patterns
The LipoFit Turbo advisory fits a recurring FDA pattern: supplements marketed as “all natural” for weight loss, sexual enhancement or other benefits have repeatedly tested positive for undeclared pharmaceuticals or toxic adulterants, prompting advisories and occasional recalls [1] [6]; historical analyses find that only a small proportion of products flagged by FDA enforcement actions are formally recalled and a meaningful share remain purchasable long after notices [5].
5. Responsible conclusion and recommended next steps for verification
Based solely on the reporting provided, the only definitive, source-cited action is the FDA advisory cautioning consumers about LipoFit Turbo and the laboratory findings of undeclared sibutramine, metformin, fluoxetine and furosemide in that product [1]; the sources do not evidence any specific retail SKUs or import alerts for “LipoFit” or “LipoFit Turbo” — to establish SKU- or lot-level recall/import-alert status requires searching the FDA’s Recalls, Market Withdrawals & Safety Alerts and the agency’s import-alert database directly or reviewing the full FDA advisory page for any linked recall notice or company press release [2] [4] [3].